Capmatinib is an effective treatment for MET-fusion driven pediatric high-grade glioma and synergizes with radiotherapy

Abstract Background Pediatric-type diffuse high-grade glioma (pHGG) is the most frequent malignant brain tumor in children and can be subclassified into multiple entities. Fusion genes activating the MET receptor tyrosine kinase often occur in infant-type hemispheric glioma (IHG) but also in other p...

Full description

Bibliographic Details

Published in:	Molecular Cancer
Main Authors:	Marc Zuckermann, Chen He, Jared Andrews, Aditi Bagchi, Roketa Sloan-Henry, Brandon Bianski, Jia Xie, Yingzhe Wang, Nathaniel Twarog, Arzu Onar-Thomas, Kati J. Ernst, Lei Yang, Yong Li, Xiaoyan Zhu, Jennifer K. Ocasio, Kaitlin M. Budd, James Dalton, Xiaoyu Li, Divyabharathi Chepyala, Junyuan Zhang, Ke Xu, Laura Hover, Jordan T. Roach, Kenneth Chun-Ho Chan, Nina Hofmann, Peter J. McKinnon, Stefan M. Pfister, Anang A. Shelat, Zoran Rankovic, Burgess B. Freeman, Jason Chiang, David T. W. Jones, Christopher L. Tinkle, Suzanne J. Baker
Format:	Article
Language:	English
Published:	BMC 2024-06-01
Subjects:	Combination therapy Pediatric-type diffuse high-grade glioma Radiosensitization MET inhibition Preclinical trials Capmatinib
Online Access:	https://doi.org/10.1186/s12943-024-02027-6